Evidence map›Paper›PMID 33889533›Full record

ArticleTranslational lung cancer research2021

Pulmonary fibrosis combined with lung cancer following lung transplantation: should we do more?

Guilin Peng, Chao Yang, Mengyang Liu, Weixue Cui, Bastian Grande, Christina Kao, Piergiorgio Solli, George Makdisi, Xin Xu, Jianxing He

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Translational lung cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 4 countries.

Guilin PengDepartment of Thoracic Surgery and Organ Transplantation, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Chao YangDepartment of Thoracic Surgery and Organ Transplantation, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Mengyang LiuDepartment of Thoracic Surgery and Organ Transplantation, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Weixue CuiDepartment of Thoracic Surgery and Organ Transplantation, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Bastian GrandeInstitute of Anesthesiology, University Hospital Zurich, Zurich, Switzerland.
Christina KaoSection of Pulmonary, Critical Care, and Sleep, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Piergiorgio SolliDepartment of Cardio-Thoracic Surgery and Hearth & Lung Transplantation, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
George MakdisiDivision of Cardiothoracic Surgery, University of South Florida, Tampa General Hospital, Tampa, FL, USA.
Xin XuDepartment of Thoracic Surgery and Organ Transplantation, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Jianxing HeDepartment of Thoracic Surgery and Organ Transplantation, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Guangzhou Medical University · CNFirst Affiliated Hospital of Guangzhou Medical University · CNAzienda USL di Bologna · ITBaylor College of Medicine · USUniversity Hospital of Zurich · CHUniversity of South Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently, lung transplantation is the standard of care for patients with end-stage lung disease, with interstitial lung disease (ILD) being the most common reason in the recent years In the other hand, in cases where stage II and III lung cancer have been identified following lung transplantation, long-term survival outcomes are poor when compared to lung cancer patients that have not received a lung transplant because the use of immunosuppressant and the problem of rejection and infection and the treatment of recurrence and so on. However, there is no statistical difference observed in stage I (pT1N0M0) patients. In this paper we report about a patient with ILD receiving left lung transplantation in the early time. A lesion of the right lung which was considered the normal ILD tissue and without enough attention. Post-transplant it showed progress and finally the whole right lung (native lung) was occupied by the tumor. Some ground glass changes could also be found in the transplanted lung several months later. A secondary lung transplant was performed for this patient, and there has been no postoperative recurrence thus far. For lung transplant patients with high-risk factors, effective surveillance methods are required for the early detection of lung cancer.

Indexed as

lung cancerlung transplantationPulmonary fibrosissurveillance

Identifiers

PMID33889533
PMCPMC8044479
OpenAlexW3142039466

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.